Finerenone shows positive results for chronic kidney disease associated with T1D
What’s happening? Today, Bayer shared data from the phase 3 FINE-ONE clinical trial. These results, which were presented at the American Society of Nephrology Kidney Week in Houston, TX, showed that finerenone (Kerendia™/Firialta™) significantly reduces urine albumin-to-creatinine ratio (UACR), a measure of kidney damage, in people with chronic kidney disease (CKD) associated with type 1 […]
See our community. See T1D.
Building awareness and understanding about T1D is more important than ever. Together, our stories change how people see T1D.
Two new trials investigating baricitinib to delay T1D
What’s happening? Earlier today, Eli Lilly and Company announced that they are launching two new clinical trials for baricitinib in type 1 diabetes (T1D). These phase 3 trials will investigate whether the drug can delay T1D onset or progression and will open for recruitment soon. Read on to learn more about the trials, why this […]
Q&A with Patti Columbe: A glimpse into her journey with Vertex’s manufactured islets
Breakthrough T1D had the pleasure of speaking with Patti Columbe, a participant in Vertex’s pivotal trial for the manufactured islet therapy zimislecel (formerly VX-880). Patti has been living with type 1 diabetes (T1D) for nearly 39 years. This is one of the most exciting T1D trials in terms of getting us closer to cures for […]
Fundraise Your Way with Breakthrough T1D
With Breakthrough T1D Your Way, you use your time, talent, and creativity to fuel type 1 diabetes research. You name it, we support you!
Ten years of impact: A closer look at Breakthrough T1D’s training awards
To drive our mission forward, Breakthrough T1D financially supports type 1 diabetes (T1D) research through training awards and grants to academic scientists or clinicians, investments in promising companies, conference support, and more. Here, we take a deeper dive specifically into our training awards offered to early-stage researchers to understand the impact and outcomes that these […]
Tzield receives voucher for expedited review in stage 3 T1D
This past week, the FDA and Sanofi, the maker of Tzield, made an important announcement. Tzield, the first disease-modifying therapy approved for delaying onset of stage 3 type 1 diabetes (T1D) in people with stage 2 T1D, has been accepted into the FDA Commissioner’s National Priority Voucher (CNPV) program for people with stage 3 T1D. […]
Civica long-acting insulin available on January 1, 2026
Nearly 3 years ago, Breakthrough T1D joined forces with Civica Rx, a non-profit pharmaceutical company, to manufacture and distribute low-cost insulins. Starting on January 1, 2026, the first of those insulins, insulin glargine-yfgn (a long-acting insulin interchangeable with Lantus®), will be available for purchase. 5 Pens, No More Than $55 – for anyone While we […]
Two truths and a lie: Separate T1D facts from fiction
There are a lot of commonly believed myths about type 1 diabetes (T1D). Play our game to separate fact from fiction.
Celebrating Halloween with type 1 diabetes
Tips for families on juggling type 1 diabetes with the super sweet fun of Halloween.
